2026 Poster Presentations

P01: Overcoming Challenges in Development of ADA Assays Across Complex Drug Modalities, Presented by Niveditha V., 360biolabs, a BioAgilytix company

P02: ADAscape: High-Resolution Polyclonal Antibody Profiling for Anti-Drug and Anti-Vector Antibodies, Presented by Oskar S., Ablevia Biotech GmbH

P03: Managing the Assay Life Cycle Within a Streamlined ADA Testing Approach for a Biologic Drug Under Clinical Development, Presented by Lode D., argenx

P04: From Standard ADA Surveillance to Fit-for-Purpose Assessment: An Adaptive Immunogenicity Strategy for a Bispecific T Cell Engager Program, Presented by Meenu P., AstraZeneca

P05: Payload Specific Antibody Discovery for ADCs from HuCAL® Phage Display Antibody Library, Presented by Renee B., Bio-Rad Laboratories

P06: Cell-Based Potency Testing of Immune Checkpoint Therapeutics, Presented by Junguk P., BPS Bioscience, Inc.

P07: Mitigating Matrix and Target Interference to Establish a Surrogate Matrix for NHP Milk ADA Assay, Presented by Moses S., Charles River Laboratories

P08: Evaluating Efficacy of Large Molecule Therapeutics Using a Multiparametric High-Content Imaging Approach, Presented by Yunpeng P., Curia Global, Inc.

P09: High-Sensitivity MAPPs for Immunogenicity Risk Assessment of Biotherapeutics, Presented by Wouter D., ImmuneSpec

P10: Primary Immune Cell-Based New Approach Methodologies for Immunogenicity Risk Assessment and Functional Characterization of Therapeutic Candidates, Presented by Sofie P., IQVIA Laboratories

P11: Decoding Immunogenicity Through Autoantibody Reactome Profiling, Presented by Dimitrios S., Johns Hopkins University

P12: Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS), Presented by Jessica P., KCAS Bio

P13: Development and Validation of a Neutralizing Antibody (Nab) Assay for a Therapeutic Enzyme Targeting Gluten Peptides, Presented by Patricia S., Labcorp Early Development Laboratories

P14: Development and Validation of an Anti-Drug Antibody Immunoassay to Detect Treatment-Induced Antibodies in Gene Therapy Studies, Presented by Chamika W., Labcorp Early Development Laboratories

P15: Vaccine Immunogenicity and Cellular Immune Responses, Presented by Yifei Y., Mayo Clinic

P16: Gene Therapy Trial Enrollment and IDE/IVDR Submission, Presented by Gerald C., Pharmaron US Lab Services

P17: Development of a Flow Cytometric Immunogenicity Assay for CAR-T Therapies: Practical Considerations, Presented by Vaishnavi M., Pharmaron US Lab Services

P18: Optimizing Brain Shuttling Antibodies for Safe Repeat Dosing and Long-Term Efficacy, Presented by Cecilia S., University of Michigan

P19: Advancing Vaccines Against Opioid Use Disorder Through Rational Design, Mechanistic Discovery, and Translational Immune Profiling, Presented by Fatima H., University of Washington